A connection between this phenomenon and the upregulation of GLUT1 in KRAS and BRAF mutant cells was recently proposed to account for the anti-tumor activity of ascorbate in colorectal cancer (Yun et al., 2015). The gene discussed is BRAF; the disease is neoplasm.